Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-27
2006-06-27
Hayes, Robert C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07067484
ABSTRACT:
The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
REFERENCES:
patent: 6280732 (2001-08-01), Caras et al.
patent: 597.503 (1994-05-01), None
patent: WO 90/02798 (1990-03-01), None
patent: WO 91/06667 (1991-05-01), None
patent: WO 94/11384 (1994-05-01), None
patent: WO 95/02421 (1995-02-01), None
patent: WO 95/27060 (1995-10-01), None
patent: WO 96/17925 (1996-06-01), None
Talmadge et al. Advanced Drug Delivery Reviews 10:247.299, 1993.
Jackowski British J Neurosurgery 9:303-317, 1995.
Bartley et al., “B61 is a ligand for the ECK receptor protein-tyrosine kinase”Nature368:558-560 (Apr. 7, 1994).
Beckmann et al., “Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors”EMBO Journal13(16):3757-3762 (1994).
Berkemeier et al., “Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB”Neuron7:857-866 (Nov. 1991).
Byrn et al., “Biological properties of a CD4 immunoadhesin”Nature344:667-670 (Apr. 12, 1990).
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy”Nature337:525-531 (Feb. 9, 1989).
Gilardi-Hebenstreit et al., “An Eph-related receptor protein tyrosine kinase gene segmentally expressed in the developing mouse hindbrain”Oncogene7:2499-2506 (1992).
Hefti, Franz, “Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections”J. of Neuroscience6(8):2155-2162 (Aug. 1986).
Heumann, Rolf, “Regulation of the Synthesis of Nerve Growth Factor”J. Exp. Biol.132:133-150 (1987).
Kaisho et al.FEBS Letters266(1,2):187-191 (Jun. 1990).
Lai et al., “An Extended Family of Protein-Tyrosine Kinase Genes Differentially Expressed in the Vertebrate Nervous System”Neuron6:691-704 (May 1991).
Leibrock et al., “Molecular cloning and expression of brain-derived neurotrophic factor”Nature341:149-152 (Sep. 14, 1999).
Maisonpierre et al., “Ehk-1 and Ehk-2: two novel members of the Eph receptor-like tyrosine kinase family with distinctive structures and neuronal expression”Oncogene8:3277-3288 (1993).
Maisonpierre et al., “Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF”Science247:1446-1451 (Mar. 23, 1990).
Rosenthal et al., “Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor”Neutron4:767-773 (May 1990).
Thoenen et al., “Physiology of Nerve Growth Factor”Physiological Reviews60(4):1284-1335 (Oct. 1980).
Tuzi et al., “eph, the largest known family of putative growth factor receptors”Br. J. Cancer69:417-421 (1994).
Zhou et al., “Isolation and Characterization of Bsk, a Growth Factor Receptor-Like Tyrosine Kinase Associated With the Limbic System”J. of Neur. Res.37:129-143 (1994).
Friden, P.M., “Receptor-mediated transport of therapeutics across the blood-brain barrier”, Neurosurgery 35(2):294-298, (Aug. 1994).
Pandey et al., “Role of B61, the Ligand for the EckREceptor Tyrosine Kinase, in TNF-α-Induced Angiogenesis”, Science 268:567-569 (1995).
Camarata et al., “Sustained Release of Nerve Growth Factor from Biodegradable Polymer Microspheres”Neurosurgery30(3):313-319 (1992).
Canal, “Degenerative Disorders”Guidelines for Drug Trials in Memory Disorders39:19-24 (1993).
Cerretti et al., “The Gene Encoding LERK-7 (EPGL&, EpI7), a Ligand for the Eph-related Tyrosine Kinases, Maps to Human Chromosome 5 at Band q21 and to Mouse Chromosome 17”Genomics35:376-379 (1996).
Cheng et al., “Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Hek4 and Sek Receptor Tyrosine Kinases”Cell79:157-168 (Oct. 7, 1994).
Davis et al., “Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity”Science266:816-819 (Nov. 4, 1994).
de Leon et al., “In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Disease”Annals of the New York Academy of Sciences777:1-13 (1996).
Drescher et al., “In Vitro Guidance of Retinal Ganglion Cell Axons by RAGS, a 25 kDa Tectal Protein Related to Ligands for Eph Receptor Tyrosine Kinases”Cell82:359-370 (1995).
Fox et al., “Atrophy of the Hippocampal Formation in Early Familial Alzheimer's Disease: A Longitudinal MRI Study of at-Risk Members of a Family With an Amyloid Precursor Protein 717 Val-Gly Mutation”Annals of the New York Academy of Sciences777:226-232 (1995).
Hefti, F., “Neurotrophic Factor Therapy for Nervous System Degenerative Diseases”Journal of Neurobiology25(11):1418-1435 (1994).
Mutson et al., “Intrastriatal and Intraventricular Infusion of Brain-Derived Neurotrophic Factor in the Cynomologous Monkey: Distribution, Retrograde Transport and Co-Localization with Substantia Nigra Dopamine-Containing Neurons”Neuroscience71(1):179-191 (1996).
Ringold et al. “Co-expression and Amplification of Dihydrofolate Reductase cDNA and theEscherichia coliXGPRT Gene in Chinese Hamster Ovary Cells”Journal of Molecular&Applied Genetics1(3):165-175 (1981).
Winslow et al., “Cloning of AL-1, a Ligand for an Eph-Related Tyrosine Kinase Receptor Involved in Axon Bundle Formation”Neuron14:973-981 (May 1995).
Barinaga, Marcia, “Receptors Find Work As Guides”, Science, vol. 269, pp. 1668-1670, Sep. 22, 1995.
Hefti et al., “Chronic Administration of Nerve Growth Factor and Other Neurotrophic Factors to the Brain”, Neurobiology of Aging, vol. 9, pp. 689-690, 1998.
Olson, Lars, “NGF and the Treatment of Alzheimer's Disease”, Experimental Neurology, vol. 124, pp. 5-15, 1993.
Olson, Lars, “Intraputaminal Infusion of Nerve Growth Factor to Support Adrenal Medullary Autografts in Parkinson's Disease- One Year Follow-up of First Clinical Trial”, Arch. Neurol., vol. 48, pp. 373-381, Apr. 1994.
Tomlinson, B.E., “Ageing and the Dementias”, Greenfield's Neuropathology, J. Hume Adams, Lee W. Duchen, Fifth edition, New York: Oxford University Press, Chapter 20, pp. 1284-1410, 1992.
Caras Ingrid W.
Winslow John W.
Agarwal Atulya R.
Dreger Ginger R.
Genentech Inc.
Hayes Robert C.
Heller Ehrman LLP
LandOfFree
AL-1 neurotrophic factor treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with AL-1 neurotrophic factor treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AL-1 neurotrophic factor treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3706867